Pharmaxis has announced that two Phase 3 trials of its Bronchitol inhaled mannitol in patients with cystic fibrosis demonstrated significant improvement in lung function with Bronchitol compared to the control group. The company also cites positive patient response to the DPI. Bronchitol has received orphan drug status in both the US and Europe. Read the company’s press release.
Positive results for Pharmaxis’s Bronchitol for CF
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
